# Tirofiban

## Aggrastat inj 12.5mg/50mL

| 藥物代碼 | IAGG |
| :--- | :--- |
| 適應症 | Unstable angina/non-ST-elevation myocardial infarction: To decrease the rate of thrombotic cardiovascular events \(combined end point of death, MI, or refractory ischemia/repeat cardiac procedure\) in patients with non-ST-elevation acute coronary syndrome \(unstable angina/non-ST-elevation myocardial infarction. |
| 副作用 | &gt;10%: Minor hemorrhage1% to 10%:Coronary artery dissection, bradycardia, edema, vasodepressor syncope, dizziness, headache, diaphoresis, nausea, pelvic pain, major hemorrhage, leg pain, fever. |
| 禁忌 | Severe hypersensitivity reaction \(ie, anaphylactic reaction\) to tirofiban or any component of the formulation; history of thrombocytopenia following prior exposure to tirofiban; active internal bleeding or a history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Dilute Aggrastat prior to administration to achieve a conc. of 50 mcg/mL. Unstable angina pectoris or non-Q-wave MI:Initial infusion rate: 0.4 mcg/kg/min for 30 min. Maintenance infusion rate: 0.1 mcg/kg/min for 48 hr & up to 108 hr. Angioplasty/atherectomy Initial bolus: 10 mcg/kg administered over 3 min immediately prior to procedure. Maintenance infusion rate: 0.15 mcg/kg/min for 36 hr. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | Compatible |
| 附帶說明 | Compatible—Maternal Benefit &gt;&gt; Embryo–Fetal Risk |
| 哺乳期用藥建議 | Hold Breast Feeding 暫停哺乳 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選  【D5W】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1.取注射用的250 mL 0.9%生理食鹽水或5%葡萄糖水溶液中抽掉50 mL丟棄。 2.加入50 mL的AGGRASTAT濃縮液於200mL的0.9%生理食鹽水或5%葡萄糖水溶液袋內，使最終濃度為50 mcg/mL。 2.依體重調整適合劑量投與藥品。 3.AGGRASTAT不可與diazepam 使用同—支靜脈輸注管。 |

